On October 9, 2025, VolitionRx Limited (VNRX) announced today that it is proposing an underwritten public offering of its common stock and accompanying common stock purchase warrants. The offering will be managed by Newbridge Securities Corporation, which will have a 30‑day option to purchase up to an additional 15% of the shares and warrants at the offering price, net of underwriting discounts and commissions. The securities are being offered under a shelf registration statement on Form S‑3 that was declared effective by the SEC on April 18, 2025.
Volition intends to use the net proceeds from the offering to fund research and continued product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions. The final terms of the offering, including the number of shares and the offering price, will depend on market conditions and other factors, and the company has stated that there is no assurance as to whether or when the offering may be completed. A preliminary prospectus supplement and accompanying base prospectus have been filed with the SEC and are available on the SEC website.
The proposed financing represents a significant capital‑raising effort for VolitionRx as it transitions from an R&D‑intensive phase to commercialization of its Nu.Q platform. By securing additional capital, the company aims to accelerate its product pipeline and expand its market presence in both veterinary and human diagnostics. The outcome of the offering will be closely watched by investors as it could materially impact the company’s ability to fund future growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.